Abstract
CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Current Pediatric Reviews
Title: The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Volume: 4 Issue: 1
Author(s): Randi J. Hagerman, Susan M. Rivera and Paul J. Hagerman
Affiliation:
Keywords: fragile X mental retardation 1 gene, Idiopathic Autism, methyl-CpG binding protein, Neuroimaging, CGG repeat
Abstract: CGG-repeat expansion mutations of the fragile X mental retardation 1 (FMR1) gene are the leading known cause of autism and autism spectrum disorders (ASD). Full mutation expansions ( > 200 CGG repeats) of the gene are generally silenced, resulting in absence of the FMR1 protein and fragile X syndrome. By contrast, smaller expansions in the premutation range (55-200 CGG repeats) result in excess gene activity and RNA toxicity, which is responsible for the neurodegenerative disorder, fragile X-associated tremor/ataxia syndrome (FXTAS), and likely additional cases of developmental delay and autism. Thus, the FMR1 gene is causative of a common (autism) phenotype via two entirely different pathogenic mechanisms, RNA toxicity and gene silencing. The study of this gene and its pathogenic mechanisms therefore represents a paradigm for understanding gene-brain relationships and the means by which diverse genetic mechanisms can give rise to a common behavioral phenotype.
Export Options
About this article
Cite this article as:
Hagerman J. Randi, Rivera M. Susan and Hagerman J. Paul, The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments, Current Pediatric Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339608783565770
DOI https://dx.doi.org/10.2174/157339608783565770 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
NO Chimeras as Therapeutic Agents in Alzheimers Disease
Current Alzheimer Research Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Novel and Emerging Drugs for Rarer Chronic Lymphoid Leukaemias
Current Cancer Drug Targets The Mammalian Tachykinin Ligand-Receptor System: An Emerging Target for Central Neurological Disorders
CNS & Neurological Disorders - Drug Targets Vaccine Therapy Update for Pregnant, Immunocompromised, and Chronic Diseases Patients
Recent Patents on Inflammation & Allergy Drug Discovery Stress, Depression and Antidepressant Treatment Options in Patients Suffering from Multiple Sclerosis
Current Pharmaceutical Design Recent Advances in the Synthesis and Development of Curcumin, its Combinations and Formulations and Curcumin-like Compounds as Anti-infective Agents
Current Medicinal Chemistry Approaching Inherited Disease on a Genomic Scale
Current Genomics Inhibitors of HIV-1 Entry and Integration: Recent Developments and Impact on Treatment
Recent Patents on Inflammation & Allergy Drug Discovery Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Targeting Stenosis with Nucleotide-Hydrolyzing Enzymes
Current Pharmaceutical Biotechnology Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene Expression Signatures in Primary Immunodeficiencies: The Experience from Human Disease and Mouse Models
Current Molecular Medicine Evaluation of Current Pharmacological Treatment Options in the Management of Rett Syndrome: From the Present to Future Therapeutic Alternatives.
Current Clinical Pharmacology Safer Vectors for Gene Therapy of Primary Immunodeficiencies
Current Gene Therapy Food Allergy
Current Pharmaceutical Design Adjuvant Treatment of Early Breast Cancer in the Elderly
Medicinal Chemistry Somatic Drugs for Psychiatric Diseases: Aspirin or Simvastatin for Depression?
Current Neuropharmacology Oxidative Phosphorylation as a Target to Arrest Malignant Neoplasias
Current Medicinal Chemistry Impact of Red Wine Consumption on Cardiovascular Health
Current Medicinal Chemistry